首页> 美国卫生研究院文献>Neuropsychiatric Disease and Treatment >Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study
【2h】

Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study

机译:一项真实世界的研究表明早期症状未改善和加重与MDD对SSRIs的治疗反应有关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

PurposeEarly improvement in major depressive disorder is defined as a reduction of ≥20% in the 17-item Hamilton Depression Rating Scale (HAM-D-17) score at the second week after initiation of treatment, predicting long-term treatment response. However, there remains no effective strategy for switching medications when a patient fails to reach early improvement at the second week. This study focused on the predictive value of early symptom changes in each item of the HAM-D-17 scale for treatment response to selective serotonin reuptake inhibitor (SSRI) monotherapy and to provide a reference for switching antidepressants to enhance early treatment efficacy.
机译:目的重度抑郁症的早期改善定义为治疗开始后第二周的17个项目汉密尔顿抑郁量表(HAM-D-17)评分降低≥20%,可预测长期治疗反应。但是,当患者在第二周未能达到早期改善时,仍然没有有效的策略来换药。这项研究集中于HAM-D-17量表中每个症状的早期症状变化对选择性5-羟色胺再摄取抑制剂(SSRI)单药治疗反应的预测价值,并为转换抗抑郁药以增强早期治疗功效提供参考。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号